Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 6/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512910 | 0.97 | BACE1 (0.43) | HDAC6BACE1RXFP1SMN1; SMN2GAA | |
| SCHEMBL7518509 | 0.84 | HDAC6 (0.47) | HDAC6BACE1RXFP1KMT2A | |
| SCHEMBL7536228 | 0.84 | BACE1 (0.44) | HDAC6BACE1GAA | |
| SCHEMBL7510758 | 0.81 | HDAC6 (0.53) | HDAC6BACE1 | |
| SCHEMBL17715612 | 0.79 | RXFP1 (0.47) | HDAC6RXFP1KMT2A | |
| SCHEMBL11932498 | 0.79 | HDAC6 (0.51) | HDAC6BACE1RXFP1KMT2A | |
| SCHEMBL13723059 | 0.79 | HDAC6 (0.44) | HDAC6BACE1RXFP1 | |
| SCHEMBL7519450 | 0.76 | CNR1 (0.36) | — | |
| SCHEMBL7513638 | 0.75 | BACE1 (0.54) | HDAC6BACE1RXFP1KMT2A | |
| SCHEMBL7514490 | 0.75 | BACE1 (0.50) | HDAC6BACE1USP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778980-B2 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130018066-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | Schering Corporation & Pharmacopeia Drug Discovery Inc. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018066-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | HDAC6 2138/4885BACE1 8/4885USP2 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.